There is a moment on every serious construction project when the thing stops being a blueprint drawing and it starts being a building. For a long time it exists only as an architect's rendering, lines on a piece of paper, a claim about what eventually stands there someday. Skeptics walk past the empty lot and see exactly that, an empty lot. And then one day the steel goes up, and the frame begins to match the drawing, beam for beam, and the people who once dismissed the rendering as half baked have to reckon with the fact that it was accurate all along.

CytoDyn just crossed that line, and back in April, the company's own CEO said so out loud. On the April call, Jacob Lalezari described the shift in language which I could not improve upon: "the moment represents a crucial inflection point, he said, as the company transitions from a company built on faith and belief and a whole lot of ifs to a company with solid, prospective, unassailable and by all accounts, remarkable data." Read that again, because it is the whole point of this post. The man running the company just told us that the rendering has become the building. Faith and belief and a whole lot of ifs was the drawing. Remarkable data is now the steel.

I want to do something here. For over a year, ever since we heard about the 5/5 still alive, I have been drawing renderings on this board, making claims about what would eventually stand on this lot before there was anything yet to see. Some of them were wrong, and I have owned those in public. But a good number of them were spot on, and the building now going up matches the drawings I posted months ago, beam for beam. So I'm about to walk the site with you and point at the places where the rendering and the building do actually line up, and yet, give you another towards the end regarding CytoDyn's transition period, because that alignment is the strongest evidence I can offer that the coming remainder of the drawing might also be sound.

The Rendering: Prime and Pair, Drawn Before It Was Proven

Months ago, before the AACR poster, I laid out the core mechanism as a claim about what the data would eventually show. I used the phrase "Prime and Pair", and described it to be a sequence: leronlimab strips the tumor's cloak by inducing PD-L1, and then the checkpoint inhibitor engages the flag that leronlimab raises. At the time, months and even years ago, I was making a rendering. A claim about a mechanism which had not yet been printed in bold at any major conference.

Then AACR came, and the building matched the drawing. As I wrote when the poster dropped, this is the Prime and Pair strategy printed in bold at AACR, explicitly stating that the target environment starts as PD-L1 low, the cloaked tumor, which leronlimab forces to induce PD-L1, stripping the cloak, allowing the ICI to enter so as to achieve long-term survival in metastatic triple-negative breast cancer. The renderings I posted essentially became the poster Pestell presented. And he took it further than I had drawn it: the poster showed the 1,214-patient genomic foundation proving that CCR5 tracks with the full exhaustion signature, PD-1, PD-L1, TIM-3, LAG-3, which elevated the entire thesis from anecdote to population-level biology. The building Pestell built was not just accurate to the drawing. It was bigger.

The Rendering: The Two Walls, Drawn Before The Cliff Came Into View

In The Reckoning Is At The Wall, I drew a rendering of the leverage inversion that the whole investment thesis rests upon. I described two walls the checkpoint empire was approaching. As I put it then, Merck made $29.5 billion from a single drug last year, Keytruda, and its main patent expires in 2028, the most financially significant patent expiration in pharmaceutical history. That was the first wall. The second wall was the one that defines the story: in microsatellite-stable colorectal cancer, 85% of all cases, Keytruda produces essentially nothing, and the SUNLIGHT standard of care sits at a real-world ORR under 3%.

I drew that as a rendering of pressure which would force the industry's hand. And in the months since then, the building has gone up exactly there. Merck did reorganize around that cliff. The patent-strategy literature confirmed that a new combination regimen carries its own patent, independent of the expiring molecule. The pressure I sketched as a future force is now visible in the industry's own corporate structure. The wall I drew is the wall they are now visibly bracing against.

The Rendering, Drawn Earliest of all: Prime and Pair, November 2025

The oldest rendering on this lot is the mechanism's own name. On November 18, 2025, months before it appeared on any poster, I laid out the Prime and Pair framework in detail: leronlimab priming the tumor by weakening it and driving PD-L1 upregulation with CD8 infiltration, then the checkpoint inhibitor pairing to finish what leronlimab started. This was another drawing put together around that time with nothing yet built beneath it. Then April 2026 came, and the AACR poster printed Prime and Pair in bold, exactly that sequence, with the genomic foundation underneath it. Five months separated the rendering from the steel.

The Rendering: Standalone Activity, Drawn Before Kasi Described It From The Podium

Here is one I am pretty proud of, because it required the most discipline to draw. In Standard of Care Illusion, I argued that the current paradigm was a holding pattern, not a harbor. I wrote that despite more than ten new drug approvals in colorectal cancer between 2010 and 2025, median overall survival dragged upward by a mere seven months, from 20 to 27 months, fifteen years of investment yielding less than one additional season of life. And into that structural vacuum, I argued, that the Prime and Pair mechanism arrives.

Then the April call came, and the trial's principal investigator described the building from the podium. The AACR poster reported 9 of 13 patients showing shrinkage or stable disease, and the webcast updated it to 15 of 22, holding at 68%, in a disease where the standard-of-care registration trial achieves a real-world ORR under 3%. As I documented from the call, Dr. Kasi described patients so heavily pretreated that some oncologists would decline to enroll them because their performance status is too compromised, and yet those patients return to work, with scheduling challenges arising because their work schedules interfere with clinic visits. The rendering said the vacuum was real and a mechanism was arriving to fill it. The building is patients going back to work in a population that otherwise would have run out of options.

Why The Alignment Matters

Here is the claim, and I make it without flinching. When a rendering and a building line up this many times, beam for beam, the drawing was not luck. The mechanism I sketched before the data existed continues to match the data arriving, because the mechanism is absolutely real. Prime and Pair drawn, then printed at AACR. The two walls drawn, now brace the industry. The standalone signal drawn, later described from the podium by the PI. That is not a run of good guesses. That is a thesis whose renderings keep becoming buildings, which is exactly what a correct thesis does.

And now the line, because it is the reason you should trust the bold one. A rendering matching a building on three floors does not necessarily prove the top floor matches as well. Everything above is the transition Lalezari named, from belief to data, and it is real and it has happened. But the final floor, the confirmed ORR overall response rate and the survival data, OS and PFS, which turn this from a remarkable early signal into a proven therapy, remains still under construction. It gets topped out at ASCO GI in January. So the rendering has become a building, and the building is not yet finished being built. The steel is up and it matches the drawing. The certificate of occupancy is January's to issue.

That is the whole picture, told at loud volume. For a year this was a lot of ifs, and I drew renderings of what the ifs might become. The CEO recently confirmed that the ifs became data. The buildings I'm able to point at, Prime and Pair, the two walls, the standalone signal, all match the drawings I posted months ago. And the one floor still going up is the one that decides everything, which is why January is not a formality but rather the icing on the cake. The blue prints were right. The building is real. And the last beam goes in at a known hour, in front of everyone.

I drew these lines when they were only lines. They are the steel frame. That is the confirmation. The finish is still ahead.

The Transition, And The Light Already Moving Toward It

Now, yet another perspective. Step back from the single building for a moment and take a look at the entire night sky which covers this field, because there is a larger thing happening, and CytoDyn is not the only bio-pharmaceutical moving toward it alone. CytoDyn moves smoothly toward it, while at the same moment, the entire industry makes its best attempt to turn in the same direction.

Here is the way to view this. Picture the line which divides a lit world from its dark counterpart, the terminating boundary between day and night. On the lit side, the hot tumors, these cancers are already bathed in immune light, where the ICI checkpoint drugs already function because there is something for them to amplify and latch onto, PD-L1. That illuminated portion of the sky is where nearly every large drug in oncology is clustered, because that is where the light of knowledge already exists. Keytruda, Opdivo, Tecentriq, all of them crowded onto the one side of the line where the light of the sun already reaches. And on the other side, in the darkness, sit the cold tumors, the vast majority of all solid cancers, microsatellite-stable colorectal among them, where no ICI checkpoint light penetrates and the great drugs of this era simply do not work.

The entire thesis of this company is that leronlimab is the one instrument built to work across that thin, fine line. Leronlimab is not another drug crowding amongst the others, onto the illuminated side, but rather it is the Primer which carries over the light of knowledge unto the dark side; it is the bridge from Cold to Hot, from Dark to Lit, thereby turning Cold tumors Hot enough for the ICI checkpoint drugs to finally do their work there. That is the position/transition CytoDyn is in, moving what is Cold to what is Hot, and it is a lonely one, which is exactly what makes it a valuable position to be in. The most crowded real estate in oncology is the Illuminated Hot-tumor side. The emptiest, and largest, is the Dark Cold side. And in this period from now to January, I draw leronlimab to operate precisely where almost nothing else can reach.

Now this is why I claim that this period is a transition and not just a haphazard claim, and it landed in the last twenty-four hours. On August 19, 2026, Merck and Moderna announced that their Phase 3 INTerpath-001 trial hit its mark: an individualized mRNA therapy added to Keytruda produced statistically significant and clinically meaningful improvements in recurrence-free survival and distant metastasis-free survival compared to KEYTRUDA alone in resected melanoma. Read what that actually is, structurally, underneath the mRNA headline. It is Merck taking its ICI checkpoint inhibitor and adding a second agent which specifically primes the patient's immune system to do more than the checkpoint inhibitor could do alone. Merck itself called it the first Phase 3 study to demonstrate a clinically meaningful improvement over KEYTRUDA alone in the adjuvant setting. The industry's largest checkpoint franchise just proved, in a pivotal trial, that the future of its own flagship drug is combination priming, adding something which wakes up the immune system such that the checkpoint inhibitor could reach further.

That is the transition CytoDyn/Leronlimab are in, stated without a shred of prophecy. The direction of the entire field is now bending toward exactly the architecture leronlimab was built on: Prime first, then Pair with the ICI checkpoint inhibitor. Merck proved the principle with an mRNA vaccine in an already lit Hot tumor. CytoDyn proposes the same principle using CCR5 blockade for Dark Cold tumors which the vaccine approach does not and can not address. Different key, different lock. The most powerful company in this space just validated the shape of the idea, publicly, in a Phase 3, the day before I wrote this. When the incumbent's own winning strategy becomes combination priming, even for Hot tumors, a proven priming agent for the markets the incumbent cannot yet reach stops being a fringe thesis and becomes the obvious next piece.

So this is where CytoDyn sits right now, at a genuine hinge of transition. The trial is fully enrolled. The data matures under the seal. The interim reads out at ESMO in October and the confirmed number at ASCO GI in January. And in the broader sky, the entire field has just turned, visibly, toward the combination-priming approach which is leronlimab's reason for being, with the largest player proving the principle in a pivotal trial this very week. The pieces are aligning, not because anything is foreordained, but because the biology of Cold tumors leaves the industry no other road, and the industry has now started traversing, unmistakably, down the LIVIMMUNE road.

I hold the honest line here as I have throughout, because it is the reason I can remain trustworthy. Merck's melanoma win is not leronlimab's colorectal win. It validates the architecture, priming plus checkpoint, not leronlimab's specific data, which still has to arrive. A field converging on combination priming makes leronlimab's thesis more credible and more commercially urgent; it does not make leronlimab's number a foregone conclusion. That number is still January's to deliver, and drugs with elegant logic fail in trials routinely. So the convergence is real and the position is real and the timing is real, and the confirmation is still ahead. The light moves toward the line. Whether leronlimab is the instrument which carries it across is what January answers.

Those renderings were right. The building is real and standing. The field itself turns toward the Dark and Cold space leronlimab occupies and leronlimab converts the Cold Dark to Illuminated sky. And the last beam goes in at a known hour, in front of everyone.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of public disclosures, published literature, and my own prior public writing, not a prediction of clinical or commercial outcomes. The CLOVER figures referenced are early and unconfirmed, reflect 350mg dosing with the 700mg cohort still maturing, and are not evidence of survival benefit. The 68% figure from the April 30 update is disease control rate, not objective response rate; confirmed adjudication is ahead at ASCO GI in January 2027, with interim data at ESMO in October 2026. The TNBC survival data is retrospective and hypothesis-generating. My past predictions matching subsequent events do not guarantee that any remaining prediction will prove correct. Mechanism and early signal are not efficacy. Drugs which make elegant biological sense fail in trials routinely, and this one may. Read the primary sources and reach your own conclusions rather than adopting mine.

Two questions came up this week which turn out to be the same question wearing two coats, and the answer to both explains the single most misread and misunderstood thing about where CytoDyn sits right now. One reader asked whether embargoed data can be shared privately with a potential partner while the public is kept in the dark. Another asked why leronlimab is stuck behind the checkpoint inhibitors in the treatment line when the science says it should be out front. The bridge between those two questions is a house, a sealed inspection, and a neighborhood full of people arguing about a price they won't ever be allowed to see.

Let's build the analogy, and then bring it home hard, because it makes the whole situation legible in a way the ticker can't do, and what it reveals is bigger than most holders have allowed themselves to believe.

The House, The Buyer, The Sidewalk

Imagine a rare house comes up for sale. Not an ordinary house. A property with something buried under it that no other lot on the market has, and no other lot can even dig up, and a mere handful of the largest buyers in the world who each, for their own survival, require exactly what is beneath it.

Out on the sidewalk, the neighborhood can see practically nothing. A sign in the yard. Lights going on and off at odd hours. An unfamiliar car in the driveway. From the street, they argue endlessly about what the place is actually worth, whether anyone is really interested in the property, whether the long quiet means the deal fell through the window or means nothing at all. The sidewalk is loud with theories precisely because the sidewalk cannot actually see inside. Noise is what people make when they are starved of the one thing that would actually settle the argument.

Inside is a different world entirely. A serious buyer does not bid on a house this valuable from the sidewalk, and a serious buyer does not care what the sidewalk even thinks. They sign a confidentiality agreement, and then they are handed the keys to every locked room. They read the full inspection report. They open the walls. They pull the survey, the soil analysis, the true condition of the foundation, everything the sign in the yard never actually says. And here is the part that matters most: that inspection is sealed. The buyer is legally bound not to post the report to the neighborhood, not to announce what they found, not to move the price by leaking what is inside. Two parties, buyer and seller, come to know the true condition of the house completely and they do that privately, while the sidewalk is left to read the lights in the windows like they read tea leaves.

That is not deception. That is how every serious transaction of real consequence has always been performed. The confidentiality is not there to fool the neighborhood. It is there to permit a real buyer to see the real truth without that truth spilling into the street and moving the price before anyone has decided upon anything. The sealed inspection is not a trick played on the crowd. It is the mechanism which makes honest evaluation even possible at all, and the crowd's exclusion from it is a feature, not a conspiracy.

Why The Sidewalk Cannot Infer The Outcome

Now hold the crucial discipline, because this is exactly where the neighborhood fools itself in both directions.

The sidewalk sees silence and fills it with a story. Some neighbors decide that the quiet means a deal is imminent, someone is clearly inside, look at the car, look at the lights. Others decide the quiet means it all collapsed, if there were really interest we would have heard by now. Both are guessing, and both are wrong to be certain, because the silence is not evidence of the outcome. The silence is evidence of the confidentiality agreement working exactly as designed. A sealed inspection produces public quiet whether the buyer loved the house or walked away. You cannot read the result off the position of the curtains.

So the honest statement, the bold one and the disciplined one at once, is this: buyers can absolutely be inside the house right now, reading the full report, precisely because the confidentiality agreement is what allows them in. And we on the sidewalk cannot know whether they are, or who they are, or what they concluded, because the entire purpose of the seal is to keep that off the street. Both halves are true. The activity may be intense. The public quiet tells you nothing about its direction. Anyone who claims the silence proves that a deal is close, or proves it is dead, is reading tea leaves in a window.

Now Bring It Home To CytoDyn

Drop the analogy onto the actual situation and every piece lands.

The house is CytoDyn, and the thing buried under it that no other lot has is a mechanism the entire checkpoint-inhibitor industry requires and cannot dig up on its own. That is not salesmanship, it is the documented state of the field. Most colorectal cancer is the microsatellite-stable type, and a June 2026 systematic review states flatly that these tumors derive little to no benefit from current immunotherapy regimens, while identifying the suppressive macrophages in the tumor as a key modulator of immunotherapy efficacy. Reprogram those M2 macrophages and the Cold locked market opens ablaze. And the thing constituting CytoDyn's foundation does exactly that: in the actual tissue of human colorectal liver metastases, blocking CCR5 drives macrophage repolarization toward the M1 anti-tumor state. That is why this is a very rare house. The one buried asset which can allow the checkpoint industry into the Cold-tumor majority is precisely the asset which the house of CytoDyn rests upon.

The buyers are the large pharmaceutical companies whose franchises are running toward a patent cliff and who requires those cold-tumor markets which they cannot currently reach. CCR5 blockade is not a nice-to-have for them, it is the very specific key to the very specific lock. The literature continues to converge upon it: reviews of Cold-tumor conversion identify CCR5 antagonism as a strategy to potentiate checkpoint inhibitors by reprogramming the microenvironment, and the independent literature shows macrophage repolarization remodeling tumors from cold to hot and increasing infiltration of activated CD8 T cells, warranting checkpoint combination. What the industry needs to grow and increase is exactly what this molecule provides.

And the buyers are being told so, out in the open, by the people selling the house. CytoDyn's CFO Robert Hoffman is on the public record describing precisely this to prospective partners: he said he is helping to put CytoDyn on the radar of potential strategic partners, namely other drugmakers whose own products could work in tandem with leronlimab, and that he plans to use the maturing data in those discussions. That is the sign in the yard and the open house, the public invitation. What Hoffman says to those partners privately, in the meetings we do not see, behind the confidentiality agreements, is exactly the sealed part, and honesty requires me to say plainly that we cannot know its contents. We know he is out there describing the asset. We do not get to hear the private pitch. That is the seal, working.

Now the two instruments which keep us on the sidewalk, because the sidewalk constantly confuses them.

The first instrument is the conference embargo. Once CytoDyn accepted presentation slots at the oncology meetings in October and January, the new efficacy data, the confirmed response and progression numbers, all became embargoed from public release, because presenting it publicly first would forfeit its novelty and the conference would pull our slot. The company itself has laid out this exact calendar publicly, for the CLOVER data. Interim results targeted for ESMO in Madrid, Spain in October 2026. Final results at ASCO GI in San Francisco in January 2027.  That embargo is why nothing material has come out since the spring. It is not the absence of an inspection. It is the seal on the report.

The second instrument is the non-disclosure agreement, and this is the answer to the first reader's question, stated boldly because it is simply true: the conference embargo governs the public, the NDA governs the private room, and they do not touch each other. A company can be entirely publicly silent, fully embargo-compliant, and simultaneously be walking a potential partner through the complete, current dataset behind a signed NDA. The embargo keeps the report off the sidewalk. The NDA is the confidentiality agreement that hands a serious buyer the keys. The embargoed data is the sealed inspection report itself, and the NDA is the legal seal on it. They are complementary, not contradictory. The public quiet since spring tells you the seal holds. It tells you nothing whatsoever about who is inside reading the quality of the foundation.

So the correct and bold reading of the silence is the sealed-inspection reading. Partners can be deep in the data right now, under NDA, reading the fully matured foundation report the public will not see until October and January. That is not a claim that a specific deal exists, we cannot know that, by design, and I will not pretend to. It is a statement about the structure, and the structure is unambiguous: the very machinery which keeps us on the sidewalk is the same machinery that hands a buyer the keys. The seller who lets the buyer in is the seller who most wants the buyer to see exactly how sound the foundation actually is. Public silence, in that light, is not the sound of nothing happening. It is the sound that the seal makes when it is doing its job.

The Second Question Is The Same House, Seen From The Inside

Now the other reader's question, the one about why leronlimab is stuck behind the checkpoint inhibitors in line, is not a separate puzzle. It is the same house viewed, but from the foundation itself.

Here is the thing the sidewalk gets backward. In the specific disease CytoDyn is currently testing, microsatellite-stable colorectal cancer, the checkpoint inhibitors are not first in line. Actually, they are nowhere in line, because they do not work there at all. This is not my opinion, it is the settled consensus of the field. As a June 2026 systematic review states plainly, most colorectal cancer is the microsatellite-stable type, and these tumors derive little to no benefit from current immunotherapy regimens. The checkpoint inhibitor is not ahead of leronlimab in this house. Rather, it cannot even get through the front door.

And the field knows this and they know precisely why, and precisely what would change it. The same review identifies that the suppressive macrophages in the tumor are increasingly recognized as a key modulator of immunotherapy efficacy in colorectal cancer. Reprogram those macrophages from the M2 tumor-protecting state to the M1 tumor-attacking state, and the Cold locked door opens to a blazing inferno. That reprogramming is exactly what CCR5 blockade does in the actual tissue of this disease: in human colorectal liver metastases, blocking CCR5 drives macrophage repolarization toward the anti-tumor state. And the independent literature keeps converging on the same door: an unrelated drug, (APG-2575) which repolarizes macrophages from M2 to M1 was shown to remodel the microenvironment from Cold to Hot and increase the infiltration of activated CD8 T cells, warranting combination with checkpoint blockade.

So the reader who asked why leronlimab sits behind the checkpoint inhibitors had the picture totally inverted, and turning it right-side up is the boldest claim in this post. Leronlimab is not waiting in line behind the checkpoint inhibitor. No. In this disease there is no line to wait in, because the checkpoint inhibitor has no working position in it whatsoever. Here, Leronlimab's job is not to advance past the checkpoint inhibitor. It is in fact, to construct the door the checkpoint inhibitor could finally walk through, in a cancer where the most successful drug class in modern oncology currently stands outside as useless. That is not moving up a queue. That is manufacturing a market worth billions where absolutely none exists today, and handing the key to it to whoever owns the Primer.

And here is the part the sidewalk has not yet absorbed: leronlimab is already showing its own strength in that role, in the data released before the seal shut it down. In the CLOVER trial, leronlimab is given on top of the standard backbone of Lonsurf and Avastin, and the early released results were just striking; circulating tumor DNA fell in every one of the first patients measured, with the magnitude of the decline tracking with the leronlimab dose. That dose-dependence is the tell, because if the backbone alone were driving the effect, the response would not scale with leronlimab. The company has been clear about the design: CLOVER evaluates two doses of leronlimab, 350mg and 700mg, on the established backbone Lonsurf and Avastin, and the leronlimab contribution is what the trial is built to isolate. I will not overstate it, this is combination data, not leronlimab alone, not monotherapy and it is still early and unconfirmed at this lower dose. But the honest bold reading is that at even 350mg, added to an approved backbone which on its own produces very modest results, leronlimab appears to be doing some serious work, in a disease where nothing in the immunotherapy toolkit works whatsoever.

That is why the market has not seen anything quite like this. The comparator regimen without leronlimab, the same Lonsurf-and-Avastin backbone, was studied in a large trial and produced a response rate in the low single digits in this population. The field has thrown checkpoint inhibitors, myeloid-targeting agents, and combination after combination at microsatellite-stable colorectal cancer, and the systematic reviews keep concluding the same thing, little to no benefit. Against that backdrop of near-uniform failure, a clean safety profile paired with a dose-dependent molecular signal in every early patient is not more of the same. It is the first thing in a very long time which looks very different in a disease defined by things which absolutely do not work.

Which is exactly why the buyers would be inside the house with the report open on the table, and why one of them cannot afford to let another one get there first. This is the competitive core of the whole situation. If leronlimab is the Primer that opens the Cold-tumor majority, then it is not just valuable to only one checkpoint owner, it is valuable to all of them, because every checkpoint inhibitor needs the same door built and opened. That turns ownership into a race. The first buyer to secure the Primer does not merely gain an asset, it denies that asset to every competitor whose franchise requires the identical key. In a field where several giants are staring at the same patent cliff and the same Cold-tumor wall, letting a rival seize the one Primer which solves both is a strategic loss no one at the table can afford to accept. The foreclosure value, keeping it away from competitors, can absolutely exceed the standalone value if there were no competitors. That is what makes a quiet house suddenly move fast.

And here is the resolution to the concern that a single acquirer would lock everyone else out, because the structure actually cuts the other way. A primer's value is maximized by being paired with as many checkpoint inhibitors as possible, across as many tumor types as possible. That argues for the drug reaching the entire field, and it can, through the shape of the deal rather than the law. A field-limited, non-exclusive licensing structure lets a primer remain available to multiple partners across multiple lanes while still rewarding its owner, so even if one company acquires CytoDyn outright, the economically rational move is frequently to keep licensing the primer broadly rather than wall it into a single franchise. So the answer to "what if one company owns it and blocks the others" is that owning it and blocking the others is usually the less profitable choice, the money is in the primer opening every door, not only the owners.

And that leads to the point one reader put more vividly than I did: if leronlimab primes Cold tumors for the entire Cold class, then it does not create one revenue stream, it potentially creates several. A primer licensed non-exclusively to pair with one company's checkpoint inhibitor in one set of tumors, and another company's in another, and a third's beyond that, is a drug earning from each pairing at once. The same molecule which makes one checkpoint inhibitor work in colorectal makes another ICI work in a different Cold tumor; each combination its own separately-patented regimen, each its own market, each its own stream back to whoever owns the Primer.

So yes, to answer the question directly and in the affirmative: the logic points toward multiple partners meaning multiple revenue streams, not one. The value of a universal key is not that it opens a single lock, it is that it opens all of them, and a key that opens all of them can be rented to everyone who owns a door. I hold one honest caveat, this is the shape of the opportunity if the drug proves out and the deals are structured this way, not a guarantee of either. But the instinct is right. A true primer is a multiple-stream asset by its nature, because the entire ICI industry requires the exact same thing it performs.

To make the analogy exact, let's address the lights in the windows. The lights are everything the sidewalk can see and reads too much into, the tape, the daily volume, the Level II order book, the drift in the share price, the tea-leaf reading of a LinkedIn post, the speculation about who was seen coming and going. That is the flickering the neighborhood watches and narrates. And it is precisely the least informative thing available, because the report which actually determines the value of the house is not in these windows. It is in the sealed room. Anyone pricing this house off the lights in the windows prices it off the one data stream engineered to reveal nothing about the foundation.

And the foundation itself, the thing the entire structure rests upon. CytoDyn's own CEO has publicly framed the inflection exactly this way, describing the company as transitioning from a company built on faith and belief and a whole lot of ifs to a company with solid, prospective, and by all accounts remarkable data. That is the claim of a sound foundation, made on the record by the person who has seen the report. It is a bold statement, and I pass it along as exactly what it is, the seller's assessment, not yet the independently adjudicated result. Which brings us to the one honest limit that governs everything above.

The two questions were never two. The house is priceless because of what the foundation is built with. The seal is what lets a buyer confirm it privately. And the reason a buyer would move at all, fast, and before a rival, is that the thing the foundation is made of, actually opens doors they cannot open alone, in specific markets they cannot afford to lose.

The One Thing The Inspection Still Has To Find

I hold the discipline that makes the bold case worth trusting, because a sealed inspection can come back either way, and honesty, that demands that I say so.

Everything above describes the structure, the mechanism, the leverage, and the machinery of private evaluation. None of it is proof that the foundation is actually sound. The published biology says CCR5 blockade should reprogram the microenvironment from M2 to M1 and therefore open the door, and the early human signal is very real. But the confirmed efficacy data, the number that tells a buyer that the foundation does actually hold the weight they require, PD-L1 upregulation, is not quite public yet but it is not final yet. It matures in the sealed room and adjudicates at the January meeting. Related macrophage-directed approaches have looked sound on inspection before but have failed to bear load in the trial. So the inspection is real, the buyers may well be inside, but the report is not yet finished. If the foundation proves sound in January, none of the leverage above is speculation, it is arithmetic. If it does not prove sound, the house was never what the sidewalk had hoped, and no confidentiality agreement would change that.

That is the honest shape of it, told at full volume. The house is rare beyond almost anything the market has ever seen. The thing constituting the foundation is something several of the largest companies in medicine require but cannot build, and cannot let a rival seize first. The public silence is the seal working, not the story ending, and it says nothing, in either direction, about who is inside. The reason leronlimab sits where it sits is not that it trails the checkpoint inhibitors, it is that it may be the one thing which allows them access at all. And the entire towering structure resides on a single inspection result, read only privately now, but revealed publicly in January.

The neighborhood argues about the lights in the windows. The report is being read in a sealed room. And we find out, at a known hour, whether the foundation holds. I know which way I lean. I also know that leaning is not the same as knowing, and that the difference is exactly what January is intended for. Both of those are true at full volume.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is analysis of published biology and public disclosures, not a prediction of clinical or commercial outcomes, and not a claim that any specific partnership, negotiation, or transaction exists; the private-evaluation discussion describes how confidentiality and conference embargoes generally work, not knowledge of any actual deal. Whether any party is evaluating the company under an NDA, and what they might conclude, is by nature not publicly knowable. The mechanistic claims are supported by the cited peer-reviewed literature; several are established in models, retrospective cohorts, or single studies and are not yet confirmed in this program's prospective human data, and closely related macrophage-directed approaches have repeatedly failed to translate to clinical benefit. The CLOVER biomarker figures are early, unconfirmed, and reflect 350mg dosing with the 700mg cohort still maturing. The 68% figure from the April 30 update is disease control rate, not objective response rate; confirmed adjudication is ahead at ASCO GI in January 2027, with interim data at ESMO in October 2026. Mechanism is not efficacy. Drugs which make elegant biological sense fail in trials routinely, and this one may. Read the primary sources and reach your own conclusions rather than adopting mine.